Comparative Pharmacology
Head-to-head clinical analysis: PROCAN versus PROCAPAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROCAN versus PROCAPAN.
PROCAN vs PROCAPAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Procainamide is a class Ia antiarrhythmic agent that blocks sodium channels, slowing conduction velocity and prolonging the refractory period. It also has weak anticholinergic effects.
Procapan is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin, increasing their concentrations in the synaptic cleft.
250 mg orally every 6 hours; extended-release product: 500 mg orally every 6 hours.
Adults: 10 mg orally three times daily; maximum 40 mg/day.
None Documented
None Documented
Procainamide: 2.5-4.7 hours (increased to 4-6 hours in elderly or heart failure; prolonged in renal impairment). NAPA: 6-9 hours (active metabolite). Clinical context: Therapeutic monitoring requires measurement of both parent drug and metabolite due to NAPA's antiarrhythmic activity.
Terminal half-life: 6.5 hours (range 4-9 h) in normal renal function; prolonged in renal impairment (up to 15 h in ESRD)
Renal: 50-67% as unchanged drug and major metabolite N-acetylprocainamide (NAPA). Biliary/fecal: <10%.
Renal: 70-80% unchanged; fecal: 10-20% as metabolites; biliary: <5%
Category C
Category C
Class Ia Antiarrhythmic
Class Ia Antiarrhythmic